Ensayos clínicos

This study is being done to determine the long-term response of patients with Lambert-Eaton Myasthenic Syndrome (LEMS) to the investigational drug [not yet approved by the Food and Drug Administration (FDA)] 3, 4-DAP. 3, 4-DAP increases the communication between the nerve and muscle by increasing the release of an important compound in this process, acetylcholine. This drug has been shown in studies done at Mayo and elsewhere to benefit patients with LEMS as well as some patients with congenital myasthenic syndromes.